Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
18.74
+0.21 (1.13%)
At close: Jun 18, 2026, 4:00 PM EDT
18.73
-0.01 (-0.08%)
After-hours: Jun 18, 2026, 5:39 PM EDT
Immunome Employees
Immunome had 206 employees as of March 31, 2026. The number of employees increased by 75 or 57.25% compared to the same quarter last year.
Employees
206
Change
75
Growth
57.25%
Revenue / Employee
$19,490
Profits / Employee
-$1,090,257
Market Cap
2.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 206 | 75 | 57.25% |
| Dec 31, 2025 | 177 | 59 | 50.00% |
| Sep 30, 2025 | 168 | 63 | 60.00% |
| Jun 30, 2025 | 155 | 77 | 98.72% |
| Mar 31, 2025 | 131 | 69 | 111.29% |
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Sep 30, 2024 | 105 | 50 | 90.91% |
| Jun 30, 2024 | 78 | - | - |
| Mar 31, 2024 | 62 | 25 | 67.57% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 293 |
| Kodiak Sciences | 130 |
| Aurinia Pharmaceuticals | 128 |
IMNM News
- 7 days ago - Immunome announces first patient dosed in Phase 1 trial of IM-1617 - TheFly
- 7 days ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - Business Wire
- 9 days ago - Immunome Transcript: AGM 2026 - Transcripts
- 9 days ago - Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 14 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Immunome announces Ringside trial met primary, secondary endpoints - TheFly
- 19 days ago - Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - Business Wire
- 20 days ago - Immunome Slides: Investor presentation - Filings